STOCKHOLM, April 25, 2025 /PRNewswire/ — Analysts, investors, and the media are invited to a presentation of RaySearch’s interim report for the first quarter of 2025, on May 9, 2025, at 10.00 am CEST. The report will be published on May 9, 2025, at 07.45 am and will be available together with presentation slides on raysearchlabs.com. Johan Löf, founder and CEO, and Nina Grönberg, CFO, will present the company’s development in a webcast. After the presentation (held in English) there is the opportunity to ask questions.
Link to webcast: RaySearch Q1, 2025
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com
Nina Grönberg, CFO, RaySearch Laboratories AB (publ)
Tel: +46 (0) 8 510 530 00
nina.gronberg@raysearchlabs.com
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch’s software has been sold to over 1,100 clinics in 47 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|
RaySearch Press Release Q1 2025 invitation presentation |
SOURCE RaySearch Laboratories
Collaboration with Adriamed drives commercial expansion and strengthens Nanox’s regional leadership Engagement supports continued growth…
TAIPEI, Taiwan & NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SL BIO Ltd. ("SL…
CEO Shaun Bagai to Discuss RenovoRx’s Commercial and Clinical Program ProgressMOUNTAIN VIEW, Calif., Jan. 14,…
Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and…
Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to…
ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading,…